Education
About Us
Working with TipRanks
Follow Us
CV Sciences (CVSI)
:CVSI
Top Page
CV Sciences
(OTC:CVSI)
Rating:45Neutral
Price Target:
$0.00
▼(-100.00%Downside)
CV Sciences (CVSI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.97M
Dividend YieldN/A
Average Volume (3M)271.26K
Price to Earnings (P/E)―
Beta (1Y)0.43
Revenue Growth-3.46%
EPS Growth49.51%
CountryUS
Employees47
SectorHealthcare
Sector Strength40
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding184,263,660
10 Day Avg. Volume376,100
30 Day Avg. Volume271,258
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-5.76
Price to Sales (P/S)0.00
P/FCF Ratio-2.37
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue0.09
Enterprise Value/Gross Profit0.77
Enterprise Value/Ebitda-0.71
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CV Sciences Business Overview & Revenue Model
Company DescriptionCV Sciences, Inc. (CVSI) is a life sciences company that operates in the hemp-based cannabidiol (CBD) sector. The company is engaged in the development, production, and sale of consumer products containing plant-based CBD. CV Sciences is known for its PlusCBD™ product line, which includes CBD oil drops, gummies, capsules, and topical creams. The company focuses on promoting health and wellness through high-quality, hemp-derived CBD products.
How the Company Makes MoneyCV Sciences generates revenue primarily through the sale of its CBD-based consumer products. The company's key revenue streams include wholesale distribution to retail partners, direct-to-consumer sales via its e-commerce platform, and sales through various online marketplaces. CV Sciences leverages its PlusCBD™ brand to capture market share in the growing CBD industry. Additionally, strategic partnerships with retailers and distributors contribute to its earnings by expanding the brand's reach and availability across various sales channels.
CV Sciences Earnings Call Summary
Earnings Call Date:May 09, 2025
(Q1-2025)
| % Change Since: 33.33%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted strong efforts in maintaining a healthy gross margin, progress in market share and product innovation, and advancements in M&A strategies. However, these positives were tempered by a decline in revenues, manufacturing challenges, and regulatory impacts. Despite the revenue decline, the company's strategic initiatives and improved cost efficiencies present an optimistic outlook.Q1-2025 Updates
Positive Updates
Healthy Gross Margin Maintained
CV Sciences maintained a gross margin of 46% in Q1 2025, demonstrating continued efficiency and cost management.
Market Share and Product Innovation
The company maintained its number one position in the natural product retail channel and increased market share. It also launched new product lines, including non-cannabinoid products under the Lunar Fox brand and new product formats like effervescent tablets.
M&A Strategy Progress
Integration of the Elevated Softgels acquisition is expected to improve cost efficiency and gross margins in the second half of 2025 through in-sourcing manufacturing.
Positive EBITDA
Achieved EBITDA of $131,000, with adjustments leading to an adjusted EBITDA loss of $311,000, indicating improved financial performance.
Improved Operating Cash Flow
The company improved its cash usage from operations to $0.1 million in Q1 2025 compared to $0.2 million in Q4 2024, moving closer to positive operating cash flow.
Negative Updates
Revenue Decline
Revenue for Q1 2025 was $3.6 million, down from $3.9 million in Q4 2024 and $4 million in Q1 2024, primarily due to an 8% decrease in unit sales.
Challenges with Manufacturing Delays
Experienced out-of-stock issues due to manufacturing delays from contract manufacturers, impacting key product availability.
Increased State Regulations Impacting Sales
State regulations have contributed to the decline in unit sales, presenting challenges in certain markets.
Company Guidance
During the first quarter of 2025, CV Sciences reported a revenue of $3.6 million, a slight decline from $3.9 million in the fourth quarter of 2024, with a gross margin of 46%. The company achieved an EBITDA of $131,000 and an adjusted EBITDA loss of $311,000, while managing to decrease SG&A expenses to $2.1 million, reflecting a 12% year-over-year reduction. Despite lower unit sales due to state regulations and supply chain disruptions, new products launched since early 2023 contributed to 35% of the quarter's revenue. The company also improved its net loss to $0.1 million, compared to $0.7 million in the previous quarter, and increased its cash position to $0.8 million by securing a $1.2 million financing agreement. Strategic initiatives, including the acquisition of Elevated Softgels and Cultured Foods, are expected to enhance cost efficiency and profitability, with positive cash flow anticipated in the latter half of 2025.CV Sciences Financial Statement Overview
Summary
CV Sciences faces significant financial challenges, including declining revenues, negative profit margins, and cash flow issues. The high debt-to-equity ratio and low equity ratio further highlight potential financial stability risks.Income Statement
The company has faced a declining revenue trend over the years, with a notable drop from 2019 to 2024. Gross profit margins have decreased significantly, indicating cost pressure. The EBIT and net profit margins are negative, reflecting operational inefficiencies and consistent net losses.35
Negative
Balance Sheet
The company exhibits a high debt-to-equity ratio, indicating potential leverage risks. The equity ratio is low, highlighting limited funding from shareholders relative to total assets. However, there has been a reduction in total liabilities over time, which is a positive sign.45
Neutral
Cash Flow
Cash flow from operations has been consistently negative, pointing to cash generation challenges. Free cash flow is also negative, indicating a lack of surplus cash after capital expenditures. The operating cash flow to net income ratio suggests operational struggles.30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.31M | 15.71M | 16.00M | 16.20M | 20.05M | 24.43M |
| Gross Profit | 6.97M | 7.17M | 7.08M | 5.55M | 8.62M | 11.01M |
| EBITDA | -1.27M | -1.86M | 3.85M | -5.66M | -14.00M | -21.72M |
| Net Income | -1.88M | -2.39M | 3.10M | -8.21M | -15.55M | -22.28M |
Balance Sheet | ||||||
| Total Assets | 7.76M | 7.93M | 9.20M | 12.74M | 18.07M | 30.63M |
| Cash, Cash Equivalents and Short-Term Investments | 812.00K | 454.00K | 1.32M | 611.00K | 1.38M | 4.02M |
| Total Debt | 1.02M | 779.00K | 442.00K | 1.53M | 922.00K | 7.77M |
| Total Liabilities | 5.87M | 6.13M | 6.30M | 13.51M | 14.52M | 19.41M |
| Stockholders Equity | 1.89M | 1.79M | 2.90M | -777.00K | 3.54M | 11.21M |
Cash Flow | ||||||
| Free Cash Flow | -482.00K | -879.00K | 2.25M | -1.89M | -7.52M | -8.36M |
| Operating Cash Flow | -424.00K | -861.00K | 2.25M | -1.89M | -7.49M | -7.30M |
| Investing Cash Flow | -68.00K | -28.00K | -156.00K | 0.00 | -35.00K | -1.06M |
| Financing Cash Flow | 648.00K | 32.00K | -1.39M | 1.12M | 4.37M | 3.27M |
CV Sciences Technical Analysis
Positive
0.04
Price Trends
0.03
Positive
0.03
Positive
0.04
Positive
Market Momentum
<0.01
Negative
59.50
Neutral
59.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVSI, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and above the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.50 is Neutral, neither overbought nor oversold. The STOCH value of 59.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CVSI.
CV Sciences Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $14.13M | ― | 3.29% | ― | -26.17% | ― | |
51 Neutral | $7.50B | 0.32 | -61.87% | 2.27% | 17.10% | 1.59% | |
45 Neutral | $6.97M | ― | -88.15% | ― | -3.46% | 49.51% | |
42 Neutral | $13.42M | ― | -336.65% | ― | -28.78% | 86.97% | |
40 Underperform | $8.19M | ― | -8.46% | ― | -9.22% | 89.90% |
* Healthcare Sector Average
Performance Comparison
CVSI
CV Sciences
0.04
-0.02
-33.33%
AYTU
Aytu BioScience
2.29
-0.57
-19.93%
YCBD
cbdMD
0.92
-3.57
-79.51%
FLGC
Flora Growth
0.59
-0.33
-35.87%
CV Sciences Corporate Events
Executive/Board ChangesShareholder Meetings
CV Sciences Holds 2025 Virtual Annual Meeting
Neutral
Jun 5, 2025
On June 2, 2025, CV Sciences, Inc. held its 2025 Annual Meeting virtually, with approximately 54.6% of the outstanding shares represented by proxy. During the meeting, stockholders elected three directors, ratified the selection of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, approved the executive officer compensation on a non-binding advisory basis, and decided that the advisory vote on executive compensation should occur every two years.
Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
CV Sciences Reports Q1 2025 Financial Results
Neutral
May 14, 2025
On May 14, 2025, CV Sciences announced its financial results for the first quarter of 2025, reporting a revenue of $3.6 million, a decrease from the previous year due to lower sales volume. Despite this, the company achieved an operating income of $11,000, an improvement from a loss in the previous year, attributed to reduced operating expenses and a reversal of accrued payroll taxes. The company also launched a new plant-based product line, Lunar Fox, targeting the growing vegan food market, marking a significant step in its transition to a global health and wellness company.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.